- Report
- October 2024
- 184 Pages
Global
From €3370EUR$3,545USD£2,831GBP
€3745EUR$3,939USD£3,146GBP
- Report
- March 2025
- 89 Pages
Global
From €5324EUR$5,600USD£4,472GBP
- Report
- January 2025
- 185 Pages
Global
From €4278EUR$4,500USD£3,594GBP
- Report
- May 2024
- 200 Pages
Global
From €3945EUR$4,150USD£3,314GBP
- Report
- May 2023
- 166 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- August 2023
- 236 Pages
Global
From €5656EUR$5,950USD£4,752GBP
- Report
- January 2024
- 150 Pages
Global
From €4611EUR$4,850USD£3,873GBP
- Report
- October 2023
- 89 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- June 2023
- 132 Pages
Global
From €903EUR$950USD£759GBP
The Next Generation Cancer Diagnostics market is a subset of the Diagnostics industry that focuses on the development of advanced technologies for the early detection and diagnosis of cancer. These technologies include molecular diagnostics, biomarkers, imaging, and other methods that can detect cancer at its earliest stages. This market is driven by the need for more accurate and timely diagnosis of cancer, as well as the increasing prevalence of the disease.
The Next Generation Cancer Diagnostics market is expected to grow significantly in the coming years, driven by the increasing demand for early diagnosis and the development of new technologies. This market is also expected to benefit from the increasing availability of data and the development of artificial intelligence and machine learning.
Some of the major players in the Next Generation Cancer Diagnostics market include Illumina, Thermo Fisher Scientific, Roche, Qiagen, and Agilent Technologies. Show Less Read more